# Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT04812808** · NA · UNKNOWN · sponsor: **Hôpital Fribourgeois** · enrollment: 10 (estimated)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** Bazedoxifene 20 mg

## Key facts

- **NCT ID:** NCT04812808
- **Lead sponsor:** Hôpital Fribourgeois
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-01
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812808, "Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04812808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*